title: Long-acting erythromycins: assessing their role in treating outpatient odontogenic infections.
abstract: Erythromycins have been part of our armamentarium against selected bacterial infections since they were discovered in 1952 and approved by the Food and Drug Administration (FDA) in 1964. In 1991, two newer, long-acting erythromycin analogues, azythromycin (brand name: Zithromax) and clarithromycin (brand name: Biaxin) were approved by the FDA. They were joined a few years later by a third long-acting form, dirithromycin (brand name: Dynabac).
authors.affiliation: Department of Oral & Maxillofacial Surgery, Baylor College of Dentistry, Texas A&M University Health Science Center, Dallas, TX, USA.
authors.forename: Roger E
authors.initials: RE
authors.lastname: Alexander
authors.forename: David M
authors.initials: DM
authors.lastname: Grogan
mesh_terms: D000553:Ambulatory Care; D000900:Anti-Bacterial Agents / Q000145:classification / Q000627:therapeutic use*; D017963:Azithromycin / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D017291:Clarithromycin / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004917:Erythromycin / Q000031:analogs & derivatives / Q000145:classification / Q000627:therapeutic use*; D006801:Humans; D014076:Tooth Diseases / Q000188:drug therapy / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents; D003692:Delayed-Action Preparations; C053853:dirithromycin; D004917:Erythromycin; D017963:Azithromycin; D017291:Clarithromycin